ALT - Altimmune jumps 13% on phase 2 pemvidutide results for obesity
2024-06-24 09:21:19 ET
More on Altimmune
- Altimmune: Going All-In On Pemvidutide
- Altimmune: A Potential Minor Player In The Massive GLP-1 Space
- Altimmune's Pemvidutide Is Not To Be Dismissed
- Altimmune Q1 2024 Earnings Preview
- Altimmune falls after Q4 results; obesity drug data released